Fluorine-18 fludeoxyglucose (FDG)
Approved Use: Indicated for PET imaging in the following settings:
Manufacturer: Various
Package Insert (Cardinal Health)
Package Insert (PETNET Solutions)
Package Insert (Triad Isotopes)
Package Insert (University of Utah)
Package Insert (Zevacor Molecular)
Clinical Guidelines:
- Oncology
- For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormality found by other testing modalities, or in patients with an existing diagnosis of cancer.
- Cardiology
- For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
- Neurology
- For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
- Adults: 5 - 10 mCi (oncology, cardiology, and neurology)
- Pediatric: 2.6 mCi (neurology)
Manufacturer: Various
Package Insert (Cardinal Health)
Package Insert (PETNET Solutions)
Package Insert (Triad Isotopes)
Package Insert (University of Utah)
Package Insert (Zevacor Molecular)
Clinical Guidelines:
- SNMMI Procedure Standard for FDG-PET Brain Imaging 2.0 (2024)
- ACR-ACNM-ASNR-SNMMI Practice Parameter for Brain PET/CT Imaging in Dementia (2020)
- EANM Practice Guideline/SNMMI Procedure Standard for Radionuclide Imaging of Pheochromocytoma and Paraganglioma (2019)
- EANM Practice Guideline/SNMMI Procedure Standard for RAIU and Scintigraphy, V 3.0 (2019)
- ACR-SPR-STR Practice Parameter for the Performance of Cardiac PET/CT Imaging (2017)
- ASNC Imaging Guidelines/SNMMI Procedure Standard for PET Nuclear Cardiology Procedures (2016)
- ACR-SPR Practice Parameter for Performing FDG-PET/CT in Oncology (2014)
- ACR-SPR Practice Parameter for the Performance of Scintigraphy for Inflammation and Infection (2014)